{"id":"NCT00730236","sponsor":"Aegerion Pharmaceuticals, Inc.","briefTitle":"A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)","officialTitle":"A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2010-09","completion":"2011-10","firstPosted":"2008-08-08","resultsPosted":"2013-02-22","lastUpdate":"2018-03-20"},"enrollment":29,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Homozygous Familial Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"AEGR-733","otherNames":["lomitapide","BMS-201038"]}],"arms":[{"label":"AEGR-733","type":"EXPERIMENTAL"}],"summary":"The goal of this trial is to study the effects of AEGR-733 on LDL cholesterol, other lipids as well as measures of safety over the long-term.","primaryOutcome":{"measure":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Lomitapide Escalated","deltaMin":-40.1,"sd":31.25}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States","Canada","Italy","South Africa"]},"refs":{"pmids":["17215532","36520008","26723464","25897792"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":29},"commonTop":["Diarrhoea","Nausea","Vomiting","Dyspepsia","Abdominal discomfort"]}}